company

The company's patented technologies are positioned in the growing field of tissue-engineering while using the patients' own cells for the treatment of his urologic disease.

Current indications for company's first product include treatment of urethral stricture and hypospadia.

Further intended indications are treatment of ureteral strictures, ureteral anomalies, and sever urinary bladder diseases.

All marketing and sales-related activities, from logistics up to physician trainings, manufacturing and quality assurance, are focused on achieving excellent and high quality products. We keep working hard on the development of further products to treat complex diseases in the field of urogenital system together with an interdisciplinary team composed by renowned scientists and physicians.

Leading specialized urologic centers in Europe use our first product MukoCell® in the treatment of urethral stricture.

The executive board of UroTiss is represented by Gouya Ram-Liebig, MD (research & development and production) and by Sören Liebig (regulatory affairs and finances).